Development and Validation of a Prediction Model for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients Receiving Postoperative Adjuvant Transarterial Chemoembolization

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):7. doi:10.1038/s41572-021-00245-6
   PubMed Web of Science ®Google Scholar
• Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of HBV reactivation during therapies for HCC: a systematic review. Hepatology. 2022;75(5):1257–1274. doi:10.1002/hep.32241
   PubMed Web of Science ®Google Scholar
• Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: mechanisms of progression and immunotherapy. World J Gastroenterol. 2019;25(25):3151–3167. doi:10.3748/wjg.v25.i25.3151
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl 1):4–13. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Utsunomiya T, Shimada M, Kudo M, et al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann Surg. 2015;261(3):513–520. doi:10.1097/SLA.0000000000000821
   PubMed Web of Science ®Google Scholar
• Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13(2):125–137. doi:10.1007/s12072-018-9919-1
   PubMed Web of Science ®Google Scholar
• Katz SC, Shia J, Liau KH, et al. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg. 2009;249(4):617–623. doi:10.1097/SLA.0b013e31819ed22f
   PubMed Web of Science ®Google Scholar
• Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology. 2013;57(4):1426–1435. doi:10.1002/hep.25832
   PubMed Web of Science ®Google Scholar
• Zhong BY, Jin ZC, Chen JJ, Zhu HD, Zhu XL. Role of transarterial chemoembolization in the treatment of hepatocellular carcinoma. J Clin Transl Hepatol. 2023;11(2):480–489. doi:10.14218/JCTH.2022.00293
   PubMed Web of Science ®Google Scholar
• Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36. doi:10.1016/j.ctrv.2018.11.002
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer. 2020;9(6):682–720. doi:10.1159/000509424
   PubMed Web of Science ®Google Scholar
• Chen ZH, Feng JK, Sun JX, et al. Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with bile duct tumor thrombus: a propensity score matching analysis. HPB. 2022;24(4):547–557. doi:10.1016/j.hpb.2021.09.005
   PubMed Web of Science ®Google Scholar
• Dong ZR, Zhang PF, Wang CH, et al. Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a retrospective analysis. Am J Cancer Res. 2015;5(1):450–457.
   PubMed Web of Science ®Google Scholar
• Wang H, Yu H, Qian YW, Cao ZY, Wu MC, Cong WM. Postoperative adjuvant transcatheter arterial chemoembolization improves the prognosis of patients with huge hepatocellular carcinoma. Hepatobil Pancreat Dis Int. 2021;20(3):232–239. doi:10.1016/j.hbpd.2020.12.018
   PubMed Web of Science ®Google Scholar
• Chen MY, Juengpanich S, Hu JH, et al. Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma. World J Gastroenterol. 2020;26(10):1042–1055. doi:10.3748/wjg.v26.i10.1042
   PubMed Web of Science ®Google Scholar
• Chen W, Ma T, Zhang J, et al. A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. HPB. 2020;22(6):795–808. doi:10.1016/j.hpb.2019.12.013
   PubMed Web of Science ®Google Scholar
• Wang H, Du PC, Wu MC, Cong WM. Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion. Hepatobiliary Surg Nutr. 2018;7(6):418–428. doi:10.21037/hbsn.2018.09.05
   PubMed Web of Science ®Google Scholar
• Qiu Y, Yang Y, Wang T, Shen S, Wang W. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microscopic portal vein invasion. Front Oncol. 2022;12:831614. doi:10.3389/fonc.2022.831614
   PubMedGoogle Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–380. doi:10.1002/hep.29086
   PubMed Web of Science ®Google Scholar
• Sun JJ, Wang K, Zhang CZ, et al. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion. Ann Surg Oncol. 2016;23(4):1344–1351. doi:10.1245/s10434-015-5008-z
   PubMed Web of Science ®Google Scholar
• Liang L, Li C, Wang MD, et al. Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma. J Hematol Oncol. 2021;14(1):165. doi:10.1186/s13045-021-01180-5
   PubMed Web of Science ®Google Scholar
• Zou Y, Chen Z, Lou Q, et al. A novel blood index-based model to predict hepatitis B virus-associated hepatocellular carcinoma recurrence after curative hepatectomy: guidance on adjuvant transcatheter arterial chemoembolization choice. Front Oncol. 2021;11:755235. doi:10.3389/fonc.2021.755235
   PubMed Web of Science ®Google Scholar
• Huang J, Liu FC, Li L, et al. Prognostic nomogram for hepatitis B virus-related hepatocellular carcinoma with adjuvant transarterial chemoembolization after radical resection. Am J Clin Oncol. 2020;43(1):20–27. doi:10.1097/COC.0000000000000619
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259. doi:10.1158/1078-0432.CCR-04-0713
   PubMed Web of Science ®Google Scholar
• Mao S, Shan Y, Yu X, et al. A new prognostic model predicting hepatocellular carcinoma early recurrence in patients with microvascular invasion who received postoperative adjuvant transcatheter arterial chemoembolization. Eur J Surg Oncol. 2022;49(1):129–136. doi:10.1016/j.ejso.2022.08.013
   PubMed Web of Science ®Google Scholar
• Tan LLY, Chew VTW, Syn N, et al. Effect of age on the short- and long-term outcomes of patients undergoing curative liver resection for HCC. Eur J Surg Oncol. 2022;48(6):1339–1347. doi:10.1016/j.ejso.2021.12.027
   PubMed Web of Science ®Google Scholar
• Atyah M, Zhou C, Zhou Q, et al. The age-specific features and clinical significance of NRF2 and MAPK10 expression in HCC patients. Int J Gen Med. 2022;15:737–748. doi:10.2147/IJGM.S351263
   PubMed Web of Science ®Google Scholar
• Zeng J, Lin K, Liu H, et al. Prognosis factors of young patients undergoing curative resection for hepatitis B virus-related hepatocellular carcinoma: a multicenter study. Cancer Manag Res. 2020;12:6597–6606. doi:10.2147/CMAR.S261368
   PubMed Web of Science ®Google Scholar
• Yang Q, Jin X, Ye F, et al. Safety and efficacy analysis of DEB-TACE treatment in elderly patients with hepatocellular carcinoma: a comparative cohort study. Oncol Res. 2018. doi:10.3727/096504018X15223171140640
   Google Scholar
• Pang S, Zhou Z, Yu X, et al. The predictive value of integrated inflammation scores in the survival of patients with resected hepatocellular carcinoma: a Retrospective Cohort Study. Int J Surg. 2017;42:170–177. doi:10.1016/j.ijsu.2017.04.018
   PubMed Web of Science ®Google Scholar
• Lin H, Zeng L, Yang J, Hu W, Zhu Y. A machine learning-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma. Front Oncol. 2021;11:608260. doi:10.3389/fonc.2021.608260
   PubMed Web of Science ®Google Scholar
• Li S, Wang Q, Mei J, et al. Risk factors of extra-hepatic progression after transarterial chemoembolization for hepatocellular carcinoma patients: a retrospective study in 654 cases. J Cancer. 2019;10(20):5007–5014. doi:10.7150/jca.35355
   PubMed Web of Science ®Google Scholar
• Chen C, Qiu H, Yao Y, et al. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol. 2021;45(2):101460. doi:10.1016/j.clinre.2020.05.008
   PubMed Web of Science ®Google Scholar
• Peng Z, Cao G, Hou Q, et al. The comprehensive analysis of efficacy and safety of callispheres(®) drug-eluting beads transarterial chemoembolization in 367 liver cancer patients: a multiple-center, cohort study. Oncol Res. 2020;28(3):249–271. doi:10.3727/096504019X15766663541105
   PubMed Web of Science ®Google Scholar
• Sun J, Zhou G, Xie X, et al. Efficacy and safety of drug-eluting beads transarterial chemoembolization by CalliSpheres(®) in 275 hepatocellular carcinoma patients: results from the Chinese CalliSpheres(®) Transarterial Chemoembolization in Liver Cancer (CTILC) study. Oncol Res. 2020;28(1):75–94. doi:10.3727/096504019X15662966719585
   PubMed Web of Science ®Google Scholar
• Ji M, Zou H, Shu B, et al. Prognostic analysis of hepatocellular carcinoma with macrovascular invasion after liver resection and a successful case of conversion therapy. Front Surg. 2022;9:1042431. doi:10.3389/fsurg.2022.1042431
   PubMed Web of Science ®Google Scholar
• Liu H, Yang Y, Chen C, et al. Reclassification of tumor size for solitary HBV-related hepatocellular carcinoma by minimum p value method: a large retrospective study. World J Surg Oncol. 2020;18(1):185. doi:10.1186/s12957-020-01963-z
   PubMed Web of Science ®Google Scholar
• Zhang H, Yuan SX, Dai SY, et al. Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion. World J Surg. 2014;38(4):947–957. doi:10.1007/s00268-013-2365-2
   PubMed Web of Science ®Google Scholar
• Carr BI, Guerra V, Donghia R, et al. Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. Int J Biol Markers. 2021;36(1):54–61. doi:10.1177/1724600821996372
   PubMed Web of Science ®Google Scholar
• Carr BI, Guerra V, Donghia R, et al. Identification of clinical phenotypes and related survival in patients with large HCCs. Cancers. 2021;13(4):592. doi:10.3390/cancers13040592
   PubMed Web of Science ®Google Scholar
• Hu S, Gan W, Qiao L, et al. a new prognostic algorithm predicting HCC recurrence in patients with Barcelona clinic liver cancer stage B who received PA-TACE. Front Oncol. 2021;11:742630. doi:10.3389/fonc.2021.742630
   PubMedGoogle Scholar
• Singal AG, Kudo M, Bruix J. Breakthroughs in hepatocellular carcinoma therapies. Clin Gastroenterol Hepatol. 2023;21(8):2135–2149. doi:10.1016/j.cgh.2023.01.039
   PubMed Web of Science ®Google Scholar
• Huang JT, Zhong BY, Jiang N, et al. Transarterial chemoembolization combined with immune checkpoint inhibitors plus tyrosine kinase inhibitors versus immune checkpoint inhibitors plus tyrosine kinase inhibitors for advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:1217–1228. doi:10.2147/JHC.S386672
   PubMed Web of Science ®Google Scholar
• Wu JY, Wu JY, Li YN, et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: a multicenter retrospective study. Front Oncol. 2022;12:985380. doi:10.3389/fonc.2022.985380
   PubMed Web of Science ®Google Scholar